Business
Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting
Encinitas, California--(Newsfile Corp. - March 10, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced three
About this update from Kiora Pharmaceuticals, Inc.
[{"type":"text","content":"Encinitas, California--(Newsfile Corp. - March 10, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (\"Kiora\" or the \"Company\") today announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, La., April 23-27, 2023. Further results from each of these three studies will be reported at the conference.\nA presentation will report interim results on safety, tolerability and efficacy from the ABACUS study, the ongoing, first-in-human clinical trial of KIO-301, a small-molecule photoswitch, intended to restore sight in patients with the orphan disease, retinitis pigmentosa.\nA second presentation will report on outcomes in an 8 patient clinical study of KIO-201, a crosslinked, chemically modified form of hyaluronic acid, in patients with the rare disease, persistent corneal epithelial defects (PCED).\nA third presentation will report additional results from a completed phase 1 trial for KIO-100, a DHODH inhibitor, intravitreally injected in 12 patients with autoimmune posterior uveitis, an orphan disease.\nAccepted ARVO abstracts and exposition details are listed below:\n\nEric Daniels, et al. \"An Intravitreal 'Photoswitch' Molecule (KIO-301) for Reanimation in Retinitis Pigmentosa: a first-in-human trial.\"\n\nWill present early experiences, as part of an ongoing, larger clinical trial, of the first-in-human evaluation of safety, tolerability and efficacy of KIO-301 in late-stage retinitis pigmentosa patients.\nThe initial population in the trial has advanced retinitis pigmentosa with either bare light perception or no light perception.\nPatient reported outcomes indicate an improvement in the ability to perceive light, delineate contrast between light and dark and improvement in overall vision function following KIO-301 injection.\nThere were no reported adverse events, including ocular adverse events, over the course of the study.\n\n\n\nPresentation #: 5444\nSession Title: Retinitis pigmentosa\nPlace and date: Room 353-355, April 27, 2023, 12:45 PM - 2:30 PM\n\nEnrique O. Graue-Hernandez, et al. \"KIO-201, a Crosslinked, Chemically Modified Form of Hyaluronic Acid, Improves Wound Healing in Patients with Persistent Corneal Epithelial Defect.\"\n\nKIO-201 is a potential treatment, evaluated in 5 previous corneal wound ...